Erythropoiesis-stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower "standard doses" (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking.
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis
Balleari E.;Angelucci E.;Clavio M.;Lemoli R. M.;Miglino M.;
2019-01-01
Abstract
Erythropoiesis-stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower "standard doses" (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Balleari_et_al-2019-Cancer_Medicine.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
488.32 kB
Formato
Adobe PDF
|
488.32 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
